BACKGROUND: Whether adding a first-generation anti-androgen (AA) to a luteinizing hormone-releasing hormone agonist in the radiotherapeutic management of unfavorable-risk prostate cancer (PC) reduces the risk of all-cause and PC-specific mortality (ACM and PCSM) among men within differing comorbidity subgroups is unknown. METHODS: Between 1995 and 2001, 206 men with unfavorable-risk PC were enrolled in a randomized trial comparing radiation with or without 6 months of androgen-deprivation therapy (ADT). Partial AA use (median: 4.2 months) occurred in 29 of the 102 men randomized to ADT. Cox, and Fine and Gray's regressions were used to evaluate the impact of full versus partial AA use on PCSM and ACM-risk within comorbidity subgroups. RESULTS: After a median follow-up of 16.62 years, 156 men died. In men with moderate to severe comorbidity increasing death was observed as treatment transitioned from no to partial to full ADT (P = 0.02) with an increased ACM-risk with full versus partial AA use (adjusted hazard ratio (AHR), 2.25 (95% confidence interval (CI), 0.94-5.41); P = 0.07); whereas only 1 and no PC deaths occurred in men receiving a partial versus full AA course, respectively. Among men with no or minimal comorbidity there was no decrease in ACM (AHR, 0.97 (95% CI, 0.49-1.91); P = 0.92) or PCSM-risk (AHR 0.39 (95% CI 0.07-52.18); P = 0.28) in comparing full versus partial AA use. CONCLUSION: Increasing AA use by 2 months does not appear to impact survival in men with localized unfavorable-risk PC and no or minimal comorbidity, but may shorten survival in men with moderate to severe comorbidity, raising concern regarding in whom and for how long the AA should be prescribed.
INTRODUCTION
Several prospective randomized trials have documented that the combination of radiation and androgen-deprivation therapy (RT and ADT) is superior to RT alone in the treatment of intermediateand high-risk prostate cancer (PC) [1] [2] [3] [4] [5] with respect to the end points of PC-specific and overall survival (OS). However, it remains unknown if a combined ADT approach using both a luteinizing hormone-release hormone (LHRH) agonist and an anti-androgen (AA) confers an OS advantage as compared with an LHRH agonist alone. A single randomized study addressed this question and showed a significant prolongation in overall but not PC-specific survival, and included men with locally advanced or metastatic PC treated with ADT without RT. 6 Given the survival benefit in the absence of a reduction in death from PC and lack of RT use, the question regarding the optimal extent of ADT necessary to maximize OS and minimize death from PC in men managed with RT for non-metastatic and unfavorable-risk PC remains unanswered.
It has been recently shown that in men with no or minimal comorbidity using the Adult Comorbidity Evaluation (ACE)-27 comorbidity metric, the addition of 6 months of ADT to RT was associated with both an overall and PC-specific survival benefit in men with localized, unfavorable-risk PC. 7 Conversely, among all men in the study, this improvement in OS was no longer significant in that ADT use was associated with a significant survival decrement in men with moderate-to-severe comorbidity owing to an increased risk of fatal myocardial infarction. Therefore, the question remains as to whether the survival benefit or decrement observed would persist, and in whom with respect to an individual's ACE-27 comorbidity score if treatment with 6 months of an LHRH agonist and o 6 months of a firstgeneration AA as compared with both an LHRH agonist and a firstgeneration AA for 6 months was utilized. We have previously shown that after a median follow-up of 8.2 years, the incidence of PSA recurrence was significantly increased in men who received o6 months of combined ADT owing to early termination of the AA secondary to elevated liver function tests or diarrhea as compared with those who received the full 6-month course of both the LHRH agonist and AA. 8 Therefore, using updated data with a median follow-up of 16.62 years from that prospective randomized trial of 206 men, where baseline comorbidity measured using the ACE-27 comorbidity metric was available at study outset, we now report on the impact of full (that is, 6 months) versus dose-reduced (that is, o6 months) AA use on the risk of all-cause and PC-specific mortality (ACM and PCSM) within ACE-27-defined comorbidity subgroups adjusting for age and PC prognostic factors. Patient population and treatment  A total of 206 men with the 1992 American Joint Commission on  Cancer clinical stage  9 T1b-T2bN0M0 unfavorable-risk were  enrolled in a prospective randomized trial within academic and  community-based centers in Massachusetts between 1 December  1995 and 15 April 2001 . Unfavorable risk factors included a PSA level410 ng ml − 1 (maximum 40 ng ml − 1 ), biopsy Gleason score 7-10 or radiographic evidence of extracapsular extension and/or seminal vesicle invasion by using endorectal magnetic resonance imaging. Central review of prostate needle-biopsy specimens was performed by a pathologist specializing in genitourinary pathology. Informed consent was signed by all participants prior to study entry. This trial has been registered on the National Institutes of Health Web site, http://clinicaltrials.gov, as NCT00116220. Details regarding this trial, including eligibility and exclusion criteria, randomization, stratification, treatment and quality-assurance guidelines have been previously described. 2 This retrospective review has been approved by the institutional review boards at Dana Farber Cancer Institute in Boston, MA, USA, St Elizabeth's Hospital in Boston, MA, USA and St Anne's Hospital in Fall River, MA, USA.
MATERIALS AND METHODS
ADT usage and modification The protocol regarding ADT usage, toxicity and dose modification has previously been described. 8 Briefly, patients were randomized in a 1:1 fashion to receive ADT or no ADT in conjunction with external beam radiotherapy. ADT consisted of 6 months of an LHRH agonist (leuprolide or goserelin acetate) in combination with 6 months of the nonsteroidal AA flutamide acetate. The prescription dose of flutamide acetate was 250 mg three times a day. Liver function tests including AST (aspartate aminotransferase), ALT (alanine aminotransferase), alkaline phosphate and total bilirubin levels were obtained at regular intervals. Flutamide acetate was discontinued if the ALT or AST level exceeded twice the upper limit of normal and then resumed once these levels normalized. If AST or ALT levels were elevated to twice the upper limit of normal again, flutamide acetate was permanently discontinued. Flutamide acetate was also held if the patient experienced gastrointestinal side effects including cramping, diarrhea or uncontrolled nausea, and was re-introduced once these symptoms resolved. If the patient could not tolerate the full dose of resumed flutamide acetate, then a half dose was attempted. If the half dose could not be tolerated, then flutamide acetate was discontinued permanently. The number of days each patient took flutamide acetate was recorded. All patients received 6 months of LHRH antagonist. In the men receiving dose-reduced AA, the median duration of flutamide acetate was 4.2 months (interquartile range, 3.3-5.5 months).
The ACE-27 Baseline information regarding patient health history was available prior to randomization permitting assignment of a comorbidity score using the ACE-27 metric, a validated comorbidity index designed for patients with cancer. 10 The index was used to assign grades to conditions into one of four levels of comorbidity (none, minimal, moderate and severe). For the purpose of the current analysis, comorbidity subgroups were defined as no or minimal versus moderate or severe.
Follow-up and determination of cause of death Patients were seen in follow-up at 3-month intervals for the first 2 years, every 6 months for an additional 3 years and annually thereafter. At each visit, a history and physical examination including a digital rectal examination was performed. PSA levels were obtained prior to digital rectal examination. At time of PSA failure, defined as PSA41.0 ng ml − 1 and a PSA that increased by 40.2 ng ml − 1 at two consecutive visits after treatment, additional staging studies including pelvic computed tomography scan or magnetic resonance imaging scan and a bone scan were obtained. Salvage ADT was recommended when the PSA level reached 10 ng ml
. Patients' oncologists determined the cause of death, which was updated through 21 February 2015.
Statistical methods
Comparison of the distribution of clinical characteristics at randomization stratified by receipt of combined, less than combined or no ADT. Descriptive statistics were used to enumerate the distribution of clinical characteristics including median age, median follow-up, median PSA, PSA by category (4 or less, 44-10, 410-20, 420 ng ml
), clinical T category (T2b versus T2a versus T1), ACE-27 comorbidity status (none/minimal versus moderate/severe), biopsy Gleason score (9-10 versus 8 or 4+3 versus 3+4 or less), stratified by the extent of ADT received. For the continuous covariates, a Wilcoxon's rank-sum test 11 was used to evaluate the comparison of these distributions between patients receiving combined versus less than combined ADT, whereas for categorical covariates, comparisons of categorical factors were made using a Mantel-Haenszel χ 2 -metric. 12 For the comparison of median follow-up times and their distribution, the Kaplan-Meier estimate 13 was used with a log rank P-value. In addition, a trend P-value was used to compare distribution across all three subgroups including no, dose-reduced or full dose AA.
Competing risks and Cox-regression analyses for PCSM and ACM. Univariate and multivariate Cox, 14 and Fine and Gray's 15 regressions were used to assess whether the extent of ADT was associated with the risk of PCSM and ACM, respectively, within comorbidity subgroups. This analysis was adjusted for PSA level, age, clinical T category and biopsy Gleason score as categorized above. We included interaction terms 16 between comorbidity and treatment with full ADT or treatment with RT where treatment with dose-reduced AA served as the reference group given the previously reported significant interaction between degree of comorbidity and extent of ADT. 7 For the end point of PCSM, we included a single interaction term for comorbidity and any ADT owing to no PC deaths in men with moderate or severe comorbidity who received full ADT. In order to more accurately estimate the adjusted hazard ratio (AHR) for the risk of PCSM for men who received full versus dose-reduced AA in the Fine and Gray's model among men with no or minimal comorbidity, we performed a separate non-interaction multivariable model in these men. The 95% confidence intervals (CIs) and associated P-values were calculated for each clinical factor's AHR and HR, and reported.
Estimates of ACM and PCSM. For the purpose of illustration, cumulative incidence estimates 17 of PCSM and 1-Kaplan-Meier estimates 13 of OS or ACM were calculated and graphically displayed for each comorbidity subgroup stratified by randomized treatment arm and extent of ADT received. For comparison of the estimates of ACM, the log-rank P-value was used, whereas for the comparison of PCSM estimates, a k-mean P-value was reported. The ACM plots are covariate-adjusted to reflect the results in the multivariate model and the corresponding P-values are computed using the covariate-adjusted log-rank test. 18 The 10-year point estimates and associated 95% CIs were calculated and reported for each patient subset stratified by ADT treatment received and comorbidity subgroup for each end point. A two-sided P-valueo 0.05 was considered statistically significant. SAS version 9.4 (Cary, NC, USA) was used for all calculations except for those involving cumulative incidence in which case R version 3.01 (Auckland, New Zealand) was used.
RESULTS
Comparison of the distribution of clinical characteristics at randomization stratified by receipt of combined, less than combined or no ADT As shown in Table 1 , when assessing for trend from no ADT to dose-reduced ADT to full ADT, there were no statistically significant differences in follow-up and PC prognostic factors (age, PSA, Gleason score, clinical T stage, comorbidity) with the exception of category T1, which was found in 58.90%, 41.38% and 41.35% of men receiving full, dose-reduced AA and no ADT, respectively (P = 0.04). When comparing the distribution of clinical factors between men receiving dose-reduced AA versus full ADT, men who received dose-reduced AA were statistically significantly more likely to have moderate or severe comorbidity (37.93 versus 17.81%; P = 0.03) when compared with men who received full ADT.
Competing risks and Cox-regression analyses for ACM and PCSM After a median follow-up of 16.62 years, 156 men died (76%); 29 deaths were from PC (19%) including 25 (86%) and 4 (14%) PC deaths occurring among the 157 and 49 men with no or minimal versus moderate-to-severe comorbidity, respectively ( Table 2 ). In men with moderate-to-severe comorbidity, an increased ACM risk with full as opposed to dose-reduced AA use calculated from our interaction model that approached statistical significance was observed (AHR, 2.25 (95% CI, 0.94-5.41); P = 0.07); whereas only 1 and no PC deaths occurred in men receiving a dose-reduced versus a full AA course, respectively. Among men with no or minimal comorbidity there was no decrease in ACM (AHR, 0.97 (95% CI, 0.49-1.91); P = 0.92) or PCSM risk (AHR 0.39 (95% CI 0.07-2.18); P = 0.28).
Estimates of ACM and PCSM As shown in Figure 1a , men with no or minimal comorbidity had estimates of ACM which declined as the extent of ADT received increased from none to dose-reduced AA to full ADT (P for trend = 0.05). Conversely, in men with moderate-to-severe comorbidity, the reverse trend was observed (P for trend = 0.02; Figure 1b) . Specifically, the 10-year point estimates for men with no or minimal comorbidity receiving no, dose-reduced AA or full ADT were 43.38% (95% CI, 33.19-53.12%), 30.15% (95% CI, 13.10-49.29%) and 18.90% (95% CI, 9.82-30.23%). These respective values were 57.65% (95% CI, 37.42-73.45%), 85.37% (95% CI, 0.00-99.82%) and 77.04% (95% CI, 32.06-94.19%) for men with moderate or severe comorbidity.
For men with no or minimal comorbidity, as shown in Figure 2a , the cumulative incidence estimates for PCSM were noted to decrease as the extent of ADT increased (P for trend = 0.003). In contradistinction, there was no significant trend noted in men with moderate or severe comorbidity with respect to estimate of PCSM by extent of ADT received (P for trend = 0.68; Figure 1b) . The 10-year point estimates for men with no or minimal comorbidity receiving no, dose-reduced AA or full ADT were 16.46% (95% CI 9.24-25.48%), 11.11% (95% CI 1.71-30.51%) and 1.67% (95% CI 0.13-7.92%). For men with moderate or severe comorbidity, these respective values were 4.00% (95% CI 0.27-17.40%), 9.09 (95% CI 0.40-35.25) and 0% (95% CI 0-0%). The AHR comparing full versus dose-reduced ADT was not estimable for men with moderate-to-severe comorbidity given no and 1 PC death among these men receiving dose-reduced and full ADT, respectively.
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DISCUSSION
We observed that when comparing receipt of 6 months of both the LHRH agonist and AA versus 6 months of the LHRH agonist and a median of 4.2 months of the first-generation AA, in men with unfavorable-risk localized PC and moderate-to-severe comorbidity, a near significant increase in risk of ACM was observed (AHR 2.38, P = 0.07). Conversely, no reduction in ACM was noted in men with no or minimal comorbidity (AHR, 0.97, P = 0.92) for this comparison. Moreover, a significant trend with increasing death was observed (Figure 1b ) in men with moderateto-severe comorbidity as treatment received transitioned from no to dose-reduced AA to full ADT (P = 0.02).
The clinical significance of these observations is that first, they raise the question as to whether men with moderate-to-severe comorbidity who opt for treatment with RT and ADT to manage their unfavorable-risk PC should be considered for o 6 months of AA use. Also, for men with no or minimal comorbidity, it appears that the delivery of full versus dose-reduced AA was not associated with prolonged survival (AHR = 0.97, P = 0.92) suggesting that supplementing the LHRH agonist therapy with an AA for 4 rather than 6 months may be sufficient to minimize death from PC and prolong survival as compared with no ADT use.
Several points require further discussion. First, although it is not surprising that decreasing the AA duration by~2 months did not lead to an increased risk of death in relatively healthy men, it is remarkable that adding these additional 2 months of the AA was associated with an increased risk of death in men with moderateto-severe comorbidity. Moreover, the AA used in this study, flutamide acetate, is less potent than currently employed AA agents such as enzalutamide. 19 Therefore, it is possible that the opposing effects on death of the additional 2 months of the AA in healthy versus unhealthy men may be more pronounced with modern agents. Furthermore, given that this is a retrospective review of the AA treatment actually received and the cohort of men who received o 6 months of the AA was limited to 29 of the 102 men randomized to RT and ADT across comorbidity subgroups, our conclusions are hypothesis generating and require prospective validation in a larger cohort including by other clinical trialists who may have similar data such as the Trans Tasmanian Radiation Oncology Group (TROG) 9601 investigators. Their study randomized men to 6 versus 3 versus 0 months of combined ADT for intermediate-or high-risk PC treated with RT 20 and likely some men randomized to the 6-month ADT arm prematurely stopped the AA for elevated liver function tests or gastrointestinal intolerance as occurred in our study. Second, when comparing full versus dose-reduced AA use with respect to the impact on the risk of death in men with no or minimal comorbidity, the reason there is no additional benefit with full ADT (AHR 0.97, P = 0.92) can be explained by examining the AHRs for these two treatment groups compared with the RT-only arm (AHR 0.63 and 0.65, respectively) where the point estimates for the reduction in the risk of ACM are nearly identical. Finally, a potential reason as to why the trend for men with no or minimal comorbidity, a decreasing risk in PCSM estimates (P = 0.003) as shown in Figure 2a did not translate to as large a trend for a decreasing risk in ACM estimates (P = 0.05) as shown in Figure 1a may be explained by competing risks. Specifically, 81% of deaths in this study were owing to non-PC causes, thus any reduction in PCSM is diluted and will not translate in a 1:1 fashion into a decreased risk of all-cause death. This highlights the important impact of competing risks on an individual patient's ability to derive an OS benefit from more aggressive PC therapy.
Not withstanding these considerations, increasing AA use by 2 months does not appear to impact survival in men with localized unfavorable-risk PC and no or minimal comorbidity, but may shorten survival in men with moderate-to-severe comorbidity raising concern regarding in whom and for how long the AA should be prescribed.
